IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Decheng Capital LLC

Q1 2026 Holdings

Filed 2026-05-13 | 14 holdings | $661.3M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
CG Oncology Inc(CGON)COM156944100$431.2M6,371,66965.2%
Nuvation Bio Inc.(NUVB)COM67080N101$111.3M25,954,43916.8%
Upstream Bio Inc.(UPB)COM91678A107$24.5M2,724,8683.7%
Aclaris Therapeutics, Inc.(ACRS)COM00461U105$15.2M4,041,7362.3%
Aardvark Therapeutics Inc(AARD)COM002942100$14.8M3,917,2992.2%
Lyell Immunopharma, Inc.COM55083R104$13.9M692,0502.1%
Newamsterdam Pharma Co NV(NAMS)COMN62509109$10.4M325,0571.6%
Arcus Biosciences, Inc(RCUS)COM03969F109$10.3M477,8191.6%
Revolution Medicines Inc(nsm)(RVMD)COM76155X100$9.1M93,5001.4%
Equillium Inc.(EQ)COM29446K106$8.9M4,447,3081.3%
BeyondSpring Inc.(BYSI)SHSG10830100$6.2M3,800,7020.9%
Zentalis Pharmaceuticals Inc.(ZNTL)COM98943L107$3.1M1,323,3270.5%
Krystal Biotech Inc(KRYS)COM501147102$1.9M7,3000.3%
Pyxis Oncology, Inc (formerly Apexigen)(PYXS)COM747324101$477.1K326,8100.1%